Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocovid Suprabio in Non-alcoholic Fatty Liver
NCT04704063Phase 2
Key facts
- Status
- Completed
- Start
- Jan 2021
- Primary completion
- Aug 2023
- Countries
- 1
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Drugs
- tocovid
- Conditions
- non-alcoholic fatty liver disease (NAFLD)
01
Overview
Phase 2, randomised, double-blind trial of tocovid in non-alcoholic fatty liver disease (NAFLD). Primary endpoint: Reduction of Liver Fat at 12 months. Started Jan 2021; status: completed.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
Adults aged 18-70 with a diagnosis of non-alcoholic fatty liver (NAFL) confirmed by ultrasound or Fibroscan, excluding those with other chronic liver diseases, significant comorbidities, or high alcohol consumption.
04
Endpoints
Primary
Reduction of Liver Fat
Beyond the preview
Go deeper on NCT04704063.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04704063.